This educational program consists of three presentations on residual CV risk and the role of icosapent ethyl in risk reduction beyond lowering with statins.

This course consists of the following:

• Residual CV risk in patients on statin therapy - Prof. Alberto Zambon, MD, PhD – Padua, Italy
• Exploring the role of icosapent ethyl based on current clinical evidence - Prof. Wouter Jukema, MD, PhD – Leiden, The Netherlands
• Potential mechanisms of benefit with icosapent ethyl - Prof. Chis Packard, PhD – Glasgow, UK

How to obtain your CME certificate

• Watch the three 3 lectures and answer the pre- and post-test questions
• Fill in the evaluation questions
• Download CME Certificate (if your score >70%)

After watching these three videos, the learner should be able to:

• Explain residual cholesterol and triglyceride risk
• Discuss details and findings of the REDUCE-IT trial
• Recall potential mechanisms of benefit of icosapent ethyl

Expert faculty

• Prof. Alberto Zambon, MD, PhD – Padua, Italy
• Prof. Wouter Jukema, MD, PhD – Leiden, The Netherlands
• Prof. Chis Packard, PhD – Glasgow, UK

Target audience

This educational activity is designed for all healthcare professionals with an interest in residual CV risk.

CME accreditation

This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.

Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

Funding

Funding for this educational program was provided by unrestricted educational grants from Amarin.

Questions

For questions regarding this activity, please contact us at info@pace-cme.org.